Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schwarz Omeprazole Launch Is Limited By Manufacturing Capacity

Executive Summary

The limited manufacturing capacity of Schwarz' subsidiary Kremers Urban Development Co. means the company will supply generic omeprazole to all major pharmacy chains and drug wholesalers, but will distribute to mail order operations on a limited basis

You may also be interested in...



Schwarz Omeprazole Strategy, Part 2: DTC Ads, No Further Price Cuts

Schwarz is giving generic omeprazole a marketing push into the broader proton pump inhibitor category rather than reducing price to further capture Prilosec's share in the omeprazole segment

Schwarz Omeprazole Strategy, Part 2: DTC Ads, No Further Price Cuts

Schwarz is giving generic omeprazole a marketing push into the broader proton pump inhibitor category rather than reducing price to further capture Prilosec's share in the omeprazole segment

Tidbits From The Fourth Quarter Calls, In Brief

AstraZeneca Prilosec generic erosion: AstraZeneca's Prilosec holds 47% share of total prescriptions following generic omeprazole entry in late 2002, CFO Jon Symonds says on Jan. 30 investor call. "We must, of course, be cautious with only six weeks of data available...but it's clear that the erosion rate is significantly less than that observed with either Prozac or Zestril at a similar stage, seemingly consistent with Kudco's inability to fully supply the market." Schwarz' subsidiary Kudco is distributing generic Prilosec on a limited basis due to supply constraints (1"The Pink Sheet" Dec. 16, 2002, p. 30)....Nexium ramp-up: Nexium total prescription share is over 20%, up more than eight percentage points in 2002. Share of total scripts written by gastrointestinal specialists is more than 27%...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS040964

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel